Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$5.61 -2.4%	$6.51	$5.20 ▼ $15.60	$11.02M	0.91	11,093 shs	24,986 shs
CBIO Crescent Biopharma	$15.90 -5.9%	$0.00	$11.06 ▼ $63.00	$10.91M	1.62	69,735 shs	54,356 shs
ENZN Enzon Pharmaceuticals	$0.12 +16.6%	$0.09	$0.06 ▼ $0.24	$7.42M	0.23	80,998 shs	305,626 shs
SABS SAB Biotherapeutics	$1.69 -5.1%	$1.76	$1.00 ▼ $5.01	$16.53M	0.55	66,765 shs	18,811 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	-2.43%	-3.11%	-6.93%	-34.00%	-61.59%
CBIO Crescent Biopharma	-5.92%	+6.00%	-97.93%	-97.93%	-97.93%
ENZN Enzon Pharmaceuticals	+16.60%	+43.95%	+29.27%	+12.33%	-37.41%
SABS SAB Biotherapeutics	-5.06%	-5.59%	-3.98%	+14.19%	-40.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BOLT Bolt Biotherapeutics	3.0386 of 5 stars	3.2	3.0	0.0	3.3	1.7	1.3
CBIO Crescent Biopharma	3.2011 of 5 stars	3.8	0.0	3.7	2.4	1.7	0.6
ENZN Enzon Pharmaceuticals	0.0509 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.0
SABS SAB Biotherapeutics	3.764 of 5 stars	3.5	5.0	0.0	3.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.33	Hold	$50.00	791.27% Upside
CBIO Crescent Biopharma	3.67	Strong Buy	$25.00	57.23% Upside
ENZN Enzon Pharmaceuticals	0.00	N/A	N/A	N/A
SABS SAB Biotherapeutics	3.00	Buy	$13.25	684.02% Upside

Current Analyst Ratings Breakdown

Latest ENZN, SABS, BOLT, and CBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	CBIO Crescent Biopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
6/20/2025	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/18/2025	CBIO Crescent Biopharma	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$22.00
5/20/2025	BOLT Bolt Biotherapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/15/2025	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/14/2025	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/13/2025	BOLT Bolt Biotherapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$25.00 ➝ $20.00
4/1/2025	SABS SAB Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
4/1/2025	SABS SAB Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$7.69M	1.40	N/A	N/A	$29.89 per share	0.19
CBIO Crescent Biopharma	$10K	1,033.50	N/A	N/A	$8.24 per share	1.93
ENZN Enzon Pharmaceuticals	$30K	288.43	$0.01 per share	9.54	$0.04 per share	2.92
SABS SAB Biotherapeutics	$1.32M	11.89	N/A	N/A	$2.81 per share	0.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$63.12M	-$33.40	N/A	N/A	N/A	-665.56%	-94.51%	-59.07%	8/12/2025 (Estimated)
CBIO Crescent Biopharma	-$37.88M	-$46.00	0.00	N/A	N/A	N/A	-293.92%	-206.20%	N/A
ENZN Enzon Pharmaceuticals	$780K	-$0.01	N/A	∞	N/A	N/A	-22.19%	-1.28%	8/6/2025 (Estimated)
SABS SAB Biotherapeutics	-$34.10M	-$3.70	N/A	N/A	N/A	N/A	-105.14%	-69.24%	8/6/2025 (Estimated)

Latest ENZN, SABS, BOLT, and CBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	BOLT Bolt Biotherapeutics	-$6.80	-$5.80	+$1.00	-$0.29	$0.77 million	$1.22 million
5/9/2025	Q1 2025	ENZN Enzon Pharmaceuticals	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/9/2025	Q1 2025	SABS SAB Biotherapeutics	-$1.00	-$0.56	+$0.44	-$0.56	$0.13 million	N/A
3/28/2025	Q4 2024	SABS SAB Biotherapeutics	-$1.16	-$1.23	-$0.07	-$1.23	$0.12 million	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
ENZN Enzon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SABS SAB Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	0.48	3.13	3.13
CBIO Crescent Biopharma	N/A	2.29	2.29
ENZN Enzon Pharmaceuticals	N/A	82.17	82.17
SABS SAB Biotherapeutics	0.15	1.69	1.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
CBIO Crescent Biopharma	75.19%
ENZN Enzon Pharmaceuticals	N/A
SABS SAB Biotherapeutics	7.82%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	6.10%
CBIO Crescent Biopharma	4.00%
ENZN Enzon Pharmaceuticals	0.40%
SABS SAB Biotherapeutics	27.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	90	1.92 million	1.80 million	Not Optionable
CBIO Crescent Biopharma	26	650,000	619,000	No Data
ENZN Enzon Pharmaceuticals	N/A	74.21 million	73.92 million	Not Optionable
SABS SAB Biotherapeutics	140	9.29 million	6.71 million	Not Optionable

ENZN, SABS, BOLT, and CBIO Headlines

Recent News About These Companies

SAB Biotherapeutics, Inc.: SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 9, 2025 | finanznachrichten.de

SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

May 9, 2025 | globenewswire.com

Craig-Hallum Reaffirms Their Buy Rating on SAB Biotherapeutics (SABS)

April 3, 2025 | markets.businessinsider.com

SAB Biotherapeutics, Inc.: SAB BIO Reports Full Year 2024 Operating and Financial Results

April 2, 2025 | finanznachrichten.de

SAB Biotherapeutics price target lowered to $20 from $25 at Chardan

April 2, 2025 | markets.businessinsider.com

SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024

March 31, 2025 | markets.businessinsider.com

SAB BIO Reports Full Year 2024 Operating and Financial Results

March 31, 2025 | globenewswire.com

SAB BIO to Participate in Upcoming Investor Conferences

January 31, 2025 | globenewswire.com

Strong Buy Recommendation for SAB-142: Promising Phase 1 Results and Future Market Potential in T1D Treatment

January 29, 2025 | markets.businessinsider.com

SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

January 29, 2025 | finanznachrichten.de

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

January 28, 2025 | globenewswire.com

SAB Biotherapeutics (SABS) Gets a Buy from Craig-Hallum

January 24, 2025 | markets.businessinsider.com

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

January 23, 2025 | globenewswire.com

Here’s Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10

January 6, 2025 | insidermonkey.com

SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider

December 23, 2024 | finance.yahoo.com

SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

November 9, 2024 | finance.yahoo.com

Promising Outlook for SAB Biotherapeutics’ SAB-142 in Type 1 Diabetes Treatment Drives Buy Rating

November 7, 2024 | markets.businessinsider.com

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

November 6, 2024 | globenewswire.com

Craig-Hallum Remains a Buy on SAB Biotherapeutics (SABS)

October 15, 2024 | markets.businessinsider.com

Craig-Hallum Initiates Coverage of SAB Biotherapeutics (SABS) with Buy Recommendation

October 10, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENZN, SABS, BOLT, and CBIO Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$5.61 -0.14 (-2.43%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.68 +0.06 (+1.16%)

As of 06/27/2025 06:13 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Crescent Biopharma NASDAQ:CBIO

$15.90 -1.00 (-5.92%)

As of 06/27/2025 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Enzon Pharmaceuticals OTCMKTS:ENZN

$0.12 +0.02 (+16.60%)

As of 06/27/2025 03:58 PM Eastern

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

SAB Biotherapeutics NASDAQ:SABS

$1.69 -0.09 (-5.06%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.73 +0.04 (+2.37%)

As of 06/27/2025 05:35 PM Eastern

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time